GLENMARK PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,053 INR | -0.68% |
|
+1.82% | +23.34% |
| Apr. 29 | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
| Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With an expected P/E ratio at 41.83 and 24.6 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +23.34% | 3.59B | B- | ||
| +19.98% | 43.67B | B- | ||
| +20.67% | 22.51B | B+ | ||
| +14.75% | 14.6B | - | ||
| +14.32% | 13.74B | B+ | ||
| +44.72% | 11.91B | B | ||
| -8.37% | 7.04B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +10.21% | 5.42B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GLENMARK Stock
- Ratings Glenmark Pharmaceuticals Limited
